Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4355 Target Snapshot

Cyclin-G-associated kinase · SINGLE PROTEIN · Homo sapiens

866Compounds
255Assays
31Approved Drugs
783.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt O14976. Use UniProt O14976 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt O14976 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cyclin-G-associated kinase as ChEMBL target CHEMBL4355, mapped to UniProt O14976. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cyclin-G-associated kinase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4355
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O14976
Cyclin-G-associated kinase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Cyclin-G-associated kinase is the right protein anchor across sources, using UniProt O14976 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCyclin-G-associated kinase
UniProt AccessionO14976
Component TypeProtein
Sequence Length1311 aa

Cyclin-G-associated kinase

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Cyclin-G-associated kinase, mapped to UniProt O14976. Sequence length is 1311 aa.

Mapped IDO14976
Review nameCyclin-G-associated kinase
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

31
Approved
13
Phase III
20
Phase II
19
Phase I
Assay Mix

Activity Type Distribution

IC50145.0
KI28.0
EC5011.0
KD599.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4531690 10.22 IC50 0.06 Preclinical
CHEMBL3545396 9.52 Kd 0.3 Clinical
CHEMBL81073 9.38 Kd 0.42 Preclinical
CHEMBL5415503 9.0 Kd 1.0 Preclinical
CHEMBL1287853 9.0 IC50 1.0 Approved
CHEMBL1287853 8.96 Kd 1.1 Approved
CHEMBL288441 8.89 Kd 1.3 Approved
CHEMBL607707 8.82 Kd 1.5 Clinical
CHEMBL4797973 8.82 Ki 1.5 Preclinical
CHEMBL4443342 8.72 Kd 1.9 Preclinical
Distribution

pChEMBL Value Distribution

29
5.0
66
5.5
79
6.0
85
6.5
78
7.0
52
7.5
42
8.0
31
8.5
3
9.0
2
9.5
pChEMBL
Approved Drugs

Approved Drugs

MOMELOTINIB
CHEMBL1078178
Approved 2023
PACRITINIB
CHEMBL2035187
Approved 2022
FEDRATINIB
CHEMBL1287853
Approved 2019
GILTERITINIB
CHEMBL3301622
Approved 2018
DACOMITINIB ANHYDROUS
CHEMBL2110732
Approved 2018
RIBOCICLIB
CHEMBL3545110
Approved 2017
MIDOSTAURIN
CHEMBL608533
Approved 2017
BARICITINIB
CHEMBL2105759
Approved 2017
NERATINIB
CHEMBL180022
Approved 2017
ALECTINIB
CHEMBL1738797
Approved 2015
AFATINIB
CHEMBL1173655
Approved 2013
AFATINIB DIMALEATE
CHEMBL2105712
Approved 2013
BOSUTINIB
CHEMBL288441
Approved 2012
RUXOLITINIB
CHEMBL1789941
Approved 2011
VANDETANIB
CHEMBL24828
Approved 2011
PAZOPANIB
CHEMBL477772
Approved 2009
SUNITINIB
CHEMBL535
Approved 2006
DASATINIB
CHEMBL5416410
Approved 2006
ERLOTINIB
CHEMBL553
Approved 2004
GEFITINIB
CHEMBL939
Approved 2003
IMATINIB
CHEMBL941
Approved 2001
Assay Landscape

Assay Landscape

255
Total Assays
375
Tested Compounds
2
Assay Types
Binding — 252 assays, 375 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 170 139 7.0
assay format 41 120 7.0
cell-based format 25 57 6.8
subcellular format 16 59 6.3
Functional — 3 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 0
assay format 1 1 6.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine